Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare ovarian neoplasm that occurs in young women and has a poor prognosis. The histologic diagnosis of SCCOHT can be challenging due to its rarity and relatively nonspecific histologic features, which range from the classic, first-described small cell morphology to a pattern in which there are large cells with abundant eosinophilic cytoplasm. Many entities can be in the differential diagnosis and to date, immunohistochemical stains have shown no distinctive profile and have been of limited aid. SMARCA4 (also known as BRG1) mutations have recently been reported at high frequency in these tumors. SMARCA4 is an important component of the SWI/SNF complex that regulates gene expression through alteration of nucleosome conformation. Studies to date have suggested that immunohistochemical loss of expression of SMARCA4 is associated with the presence of a SMARCA4 mutation in most cases. In this study, the sensitivity and specificity of the immunohistochemical loss of SMARCA4 expression for the diagnosis of SCCOHT is examined in the context of the differential diagnosis with other primary or metastatic ovarian tumors. All but one of the SCCOHT showed loss of SMARCA4 expression (16/17; 94%), while of 279 other tumors tested, only two tumors (one clear cell carcinoma and one ovarian melanoma) showed loss of SMARCA4 expression. We conclude that SMARCA4 immunohistochemistry is highly sensitive and specific for a diagnosis of SCCOHT and is of clinical utility in the differential diagnosis of poorly differentiated ovarian tumors.
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Key Words: small cell carcinoma of ovary, hypercalcemic type, SMARCA4, immunohistochemistry (Am J Surg Pathol 2016;40:395-403) S mall cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, poorly differentiated ovarian malignancy of uncertain lineage, which presents in young women and is associated with poor clinical outcome and, in many cases, hypercalcemia. 1 Histologically, the tumor is usually composed of small, hyperchromatic, mitotically active cells with follicle-like spaces, although up to 40% of cases demonstrate areas of large cell morphology. 1, 2 Several recent studies have reported a high frequency of inactivating, predominantly nonsense, splice-site, or frameshift SMARCA4 (also known as BRG1) mutations in these tumors, which lead to loss of protein expression. [3] [4] [5] [6] No other recurrent mutations were detected in SCCOHT in these studies. 4 SMARCA4 acts as a catalytic ATPase subunit in the Switch/Sucrose Non Fermentable (SWI/SNF) complex, which regulates gene expression by remodeling chromatin to alter nucleosome conformation. 7 In non-neoplastic cells, this complex acts to regulate the specific gene expression programs in different cell types, 7 whereas in vitro studies on neoplastic cells have suggested a role for the SWI/SNF complex in the regulation of expression of both oncogenes and tumor-suppressor genes. 8 Other key subunits of SWI/ SNF include SMARCB1, ARID1A, and ARID1B. It is estimated that mutations in SWI/SNF components occur in up to 20% of tumors, with mutations in SMARCA4 being among the most common. 9 SMARCA4 mutations (predominantly missense) have been previously reported in carcinomas of multiple sites, including lung 10, 11 and pancreas, 12 and even in ovarian epithelial neoplasia 13 and endometrial carcinoma. 14 However, the significance of the SMARCA4 mutation in the process of tumorigenesis in these complex, genetically unstable carcinomas is unclear. In contrast, as the only recurrent mutation demonstrated in SCCOHT to date, 4 SMARCA4 mutation appears likely to be a major driver in SCCOHT tumorigenesis.
Immunohistochemical studies on SMARCA4 expression have demonstrated loss of expression in the vast majority of SCCOHT with confirmed SMARCA4 mutations, suggesting that the presence of SMARCA4 mutation can be inferred using immunohistochemistry. 3, 4 In addition, Ramos et al 5 performed immunohistochemical analysis on a range of primary ovarian epithelial, sex cord stromal, and germ cell tumors and demonstrated that only 2 of 485 tumors showed loss of expression of SMARCA4. Both tumors with loss of SMARCA4 expression were ovarian clear cell carcinomas (CCCs). These initial results suggested that in the differential diagnosis of primary ovarian tumors, loss of SMARCA4 expression is both sensitive and specific for SCCOHT. However, the data available on SMARCA4 expression in rare tumors such as small cell carcinoma of ovary, pulmonary type (SCCO-PT), and granulosa cell tumor, juvenile-type (GCT-J), are currently very limited, because of the low numbers of tumors tested to date. Prior immunohistochemical studies have focused exclusively on the pattern of SMARCA4 expression of primary ovarian tumors. However, the ovary is a frequent site of metastasis, and the differential diagnosis between a SCCOHT and various metastatic tumors can represent a diagnostic challenge. In this study, we investigated SMARCA4 immunohistochemical expression in a range of tumors that may secondarily involve the ovary. Furthermore, we aimed to expand our knowledge of the SMARCA4 expression profiles of primary ovarian tumors, some of which may feature in the differential diagnosis of SCCOHT, by studying cohorts of both common ovarian epithelial tumors and rarer ovarian tumor types, including sex cord stromal tumors (SCSTs).
METHODS

Case Selection
Having secured institutional review board approval, 17 SCCOHT cases were identified from the pathology database of the participating institutions, including the personal consult files of 3 expert gynecologic pathologists , and sex cord stromal tumor not otherwise specified [n = 3]). Nonovarian tumors tested included lung small cell carcinoma (n = 26), small cell carcinoma of uterine cervix (n = 2) or corpus (n = 1), gynecologic tract melanoma (n = 31), and desmoplastic small round cell tumor (DSRCT) (n = 36). Seven of the lung SCCs tested were from a metastatic site (liver), whereas 18 were from the primary lung lesion. Of the 3 melanomas involving the ovary, 1 was of unknown primary site, whereas the remaining 2 were metastases from primary skin melanomas. The remaining melanomas tested involved the vulva (n = 14), vagina (n = 12), and cervix (n = 2).
Immunohistochemistry
One whole formalin-fixed, paraffin-embedded section of tumor from each case was evaluated using a murine monoclonal SMARCA4 antibody raised against amino acids 209-296, mapping near the N-terminus of SMARCA4 of human origin (clone G-7; Santa Cruz Biotechnology, Dallas, TX). All staining procedures were performed on a Leica Bond-RX (Leica, Buffalo Grove, IL) automated stainer platform. For the immunohistochemical detection of brg1, mAb G-7 (SC17796; Santa Cruz Biotechnology) was used at a dilution of 1:500 (0.4 mg/mL). Primary incubation time was 30 minutes. Heat-based antigen retrieval was used with the help of an EDTA-based retrieval buffer (ER2; Leica) for 30 minutes. As secondary reagent, a polymer detection kit (Refine; Leica) was used. In tumors with loss of SMARCA4 protein expression, positive staining of endothelial cells and stromal cells was used as an internal positive control. A tumor was adjudged to demonstrate loss of expression when all tumor cells were negative for SMARCA4 immunostaining, in the presence of a positive internal control. Reduced, focal, or attenuated tumor positivity was counted as retention of protein expression. Non-SCCOHT tumors with highly attenuated or negative SMARCA4 staining underwent repeat staining using the same technique for confirmation of the initial result.
RESULTS
The results of SMARCA4 immunohistochemistry are presented in Table 1 . Sixteen of 17 SCCOHT cases tested (94%) demonstrated complete loss of expression of SMARCA4 (Fig. 1) . The presence of an in-frame deletion leading to the production of a truncated, nonfunctional protein had previously been reported in the single SCCOHT case with retained SMARCA4 expression. 4 Among all ovarian carcinoma subtypes tested, only 1 CCC showed complete loss of SMARCA4 expression (1/37; 3%) (Fig. 2) . The SMARCA4-negative CCC was a stage IV, widely disseminated tumor with both clear and oxyphilic morphology and papillary and tubulocystic architecture. The tumor occurred in a 49-year-old woman who died from disease within 1 year of diagnosis, despite treatment with multiple lines of chemotherapy. All ovarian SCSTs tested showed uniform positive SMARCA4 staining, including GCT-A, GCT-J, Sertoli-Leydig cell tumor, and gynandroblastoma ( Fig. 3 ). All SCCO-PT, high-grade serous carcinoma, and OEC cases tested showed retained SMARCA4 expression ( Fig. 4) .
One of 31 melanomas tested showed complete loss of SMARCA4 expression (3%), an ovarian melanoma with no other known primary site. Histologically, the tumor did not morphologically resemble SCCOHT, being composed of cells with abundant cytoplasm, small round nuclei, and prominent melanotic pigment (Fig. 5 ). All lung SCCs, gynecologic tract SCCs, and DSRCTs tested showed strong retained expression of SMARCA4 (Fig. 6) .
Thus, in the cohort studied, loss of SMARCA4 expression had a sensitivity of 94% and a specificity of 99.3% for the diagnosis of SCCOHT.
DISCUSSION
In this immunohistochemical study of a range of primary ovarian and nonovarian tumors, we have demonstrated that loss of SMARCA4 expression is both sensitive and specific for the diagnosis of SCCOHT and thus is of clinical utility in the differential diagnosis of a wide range of poorly differentiated tumors involving the ovary.
The spectrum of small cell and large cell phenotypes that may be encountered in SCCOHT result in many tumors potentially being in the differential diagnosis, 15 and no immunohistochemical findings had previously been shown to be discriminative for the diagnosis of SCCOHT.
The classic morphologic appearance of SCCOHT involves sheets of small, uniform, mitotically active cells with variously conspicuous follicle-like spaces. In up to 40% of tumors, however, a component of larger, more pleomorphic and sometimes rhabdoid-like cells can be seen. 1, 2, 16 When these large cell areas predominate, the tumor is referred to as "SCCOHT, large cell variant." 1 Immunohistochemical studies have described a nonspecific profile of variably intense positive staining for EMA, pan-keratin, WT1, and CD10 and negativity for ainhibin and TTF-1. 2 Variable immunohistochemical staining for neuroendocrine markers has been reported, with positivity for chromogranin or synaptophysin identified in a minority of cases. 1, 2 Although the diagnosis of SCCOHT can be made on morphologic grounds in most cases if the observer has experience with the entity, most pathologists who first encounter this neoplasm will have seen no prior examples. Furthermore, even those who have seen 1 or more examples can have diagnostic difficulties, as rare primary ovarian epithelial tumors such as SCCO-PT or malignant sex cord tumors not otherwise specified can histologically resemble SCCOHT. In addition, poorly differentiated tumors in the sex cord group, which often occur in the young, can demonstrate a nonspecific morphologic and immunohistochemical profile, with attenuated staining for traditional markers of sex cord stromal differentiation such as calretinin and inhibin. Our study confirms the initial findings of Ramos et al 5 and Karanian-Phillipe 17 that SMARCA4 immunohistochemistry can help in the differential diagnosis between these tumors and SCCOHT. This paper also highlights a rare diagnostic pitfall, which can occur with the use of SMARCA4 immunohistochemistry in SCCOHT, where there is retention of protein expression despite the presence of a SMARCA4 in-frame deletion (previously demonstrated in the single SMARCA4positive SCCOHT by Jelinic et al 4 
). Thus, SMARCA4
immunohistochemical results should be interpreted in the context of the clinical scenario and morphologic features, and further testing, such as sequencing analysis, can be undertaken when diagnostic uncertainty remains.
Another recent paper reports loss of SMARCA4 expression in undifferentiated and dedifferentiated endometrial carcinomas. 18 As the undifferentiated component of dedifferentiated carcinomas showed preferential loss of SMARCA4 expression, it was hypothesized that SWI/SNF alterations may play a role in the progression and/or dedifferentiation of certain ovarian endometrioid carcinomas of the endometrium. Undifferentiated and dedifferentiated carcinomas of the ovary are extremely uncommon tumors 19, 20 but do show some morphologic similarity to SCCOHT. In particular, the large cell variant of SCCOHT may be histologically similar to rhabdoid tumor cells that are sometimes found in undifferentiated and dedifferentiated carcinomas. As the median age of patients with undifferentiated and dedifferentiated carcinomas is 51 to 59 years, [19] [20] [21] most cases should be distinguishable by virtue of the patient's age, although this is not a highly specific data point. Any differentiated endometrioid carcinomatous component would support a diagnosis of dedifferentiated carcinoma. Our own anecdotal experience also indicates that cytokeratin and EMA expression tends to be much more diffusely distributed in SCCOHT than in undifferentiated and dedifferentiated carcinomas. Last, the role that SMARCA4 plays in each tumor type appears to be different, with SMARCA4 germline mutation being common in SCCOHT 4-6,22-24 and acquired SMARCA4 mutations being more common in undifferentiated and dedifferentiated carcinomas, particularly in the setting of defective DNA mismatch repair. 18 There can also be extensive morphologic and immunohistochemical overlap between metastatic tumors to the ovary and SCCOHT. SMARCA4 immunohistochemistry represents a further diagnostic tool in the differential diagnosis between metastatic small cell carcinoma involving the ovary and SCCOHT, adding to the current approach, which utilizes a combination of clinicoradiologic correlation, careful tumor sampling to detect a minor differentiated component (for example, with mucinous or endometrioid features), and assessment of additional informative primary site-specific parameters such as evidence of human papilloma virus infection in metastatic cervical tumors. 25, 26 In young patients, DSRCT can be an important differential diagnosis of SCCOHT. Although DSRCT is considered to have a characteristic immunohistochemical profile and intra-abdominal pattern of widespread serosal involvement, SMARCA4 immunohistochemistry can be helpful in ruling out a SCCOHT with extensive intraperitoneal dissemination. 27 In common with the results of Ramos et al, 5 we found that rare ovarian CCCs demonstrate loss of SMARCA4 expression. This finding is intriguing in light of the high prevalence of mutations in ARID1A (another key component of the SWI/SNF complex) in ovarian CCC (approximately 50%). 28, 29 However, it should be noted that ARID1A mutations also occur in up to one third of ovarian endometrioid adenocarcinomas, 29 which consistently show retention of SMARCA4 expression. 5 In addition, it is provocative to reflect on the fact that CCC is the second most common ovarian tumor associated with paraneoplastic hypercalcemia. 30 The only other tumor in our study cohort with loss of SMARCA4 expression was a melanoma that involved the ovary and was of uncertain primary origin. As SMARCA4 mutations have been reported in up to 10% of melanomas, 9 this result was not unexpected but highlights a potential diagnostic pitfall. However, a wider range of immunohistochemical markers, including melanocytic markers such as SOX10, S100, MelanA, and HMB45, should facilitate accurate pathologic diagnosis.
The histogenesis of SCCOHT and where it falls precisely in the categorization of ovarian tumors has not been established to date. Dr Robert E Scully, who first described this entity, placed it in the miscellaneous category of tumors. 31 Whereas features such as patient age distribution, immunohistochemical positivity for calretinin, and frequent presence of follicle-like spaces within the tumor have been previously proposed as evidence for a sex cord lineage, other features such as negative a-inhibin and positive EMA immunohistochemistry argue against a sex cord origin. 2 Witkowski et al 16 noted focal rhabdoid morphology in the large cell areas of SCCOHT and postulated that there may be a developmental link between extracranial atypical teratoid/ rhabdoid tumors and SCCOHT, in light of the fact that a SMARCA4 mutation-associated familial rhabdoid tumor predisposition syndrome has been described in recent years. 32, 33 The majority of familial rhabdoid tumors are associated with the presence of a germline SMARCB1 mutation, 34, 35 another key component of the SWI/SNF complex. Foulkes et al 36 have suggested that SCCOHT should be renamed "malignant rhabdoid tumor of ovary (MRTO)" in light of these observations and longstanding issues with the nomenclature used in SCCOHT, including both the use of terminology such as "large cell variant of small cell carcinoma, hypercalcemic subtype," which some find confusing, and the fact that SCCOHT may be associated with normal serum calcium levels. However, in light of the fact that this entity has been called "small cell carcinoma of ovary, hypercalcemic type" for almost 40 years, 31 has accumulated an extensive body of literature over that time, and is widely recognized under this name, we think that the proposal to change the current nomenclature is premature. Furthermore, although SCCOHT can in some cases demonstrate the presence of rhabdoid cells (a feature in common with rhabdoid tumors), the majority do not, a fact that makes it inappropriate to consider them synonymous. Rather than exchanging one inexact, histology-based label with another, it is preferable to await further developments in the field of molecular pathology to establish the nomenclature that is best for this tumor. In the future, it may be considered appropriate to create a "SMARC-gene mutated" tumor category involving multiple sites, which is principally defined not by histologic features but by the presence of such mutations. At this time, however, we favor retention of the current, well-established term.
In summary, the loss of expression of SMARCA4 on immunohistochemistry can be considered highly sensitive and specific for the diagnosis of SCCOHT. SMARCA4 immunohistochemistry can be used both in the differential diagnosis of poorly differentiated primary ovarian tumors and to differentiate metastatic tumors from SCCOHT.
